Immutep (ASX:IMM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Immutep (ASX:IMM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
TACTI-004 Update & Positive Mature Data from INSIGHT-003
Immutep reports positive mature survival data in 1L NSCLC from INSIGHT-003; TACTI-004 trial discontinued with ongoing root cause analysis
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Ceasing to be a substantial holder
Change in substantial holding
Becoming a substantial holder
Change in substantial holding
Immutep Presents Positive IMP761 Phase I Data at EULAR 2026
Change in substantial holding
Efti immune activation associated with improved survival
Change in substantial holding
Ceasing to be a substantial holder
Immutep Receives Nasdaq Notice of Bid Price Deficiency
Immutep Quarterly Activities Report and Appendix 4C
Immutep halts TACTI-004 Phase III lung cancer trial after futility analysis; ongoing root cause review and strong cash position
Change in substantial holding
Change in substantial holding
Change in substantial holding
Abstract on Efti accepted for presentation at ASCO 2026
Change in substantial holding
Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
Immutep awarded FDA Orphan Drug Designation for eftilagimod alfa in Soft Tissue Sarcoma
